Timothy Pflederer is a Nephrology physician. OpenAlex indexes 22 publications with 607 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
420 NE Glen Oak Ave Ste 401
Peoria, IL 616033112
Telephone
309-676-8123Provider last certified this registry record 11 Feb 2025.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Bard Peripheral Vascular, Inc.Program year20254 payments
- NxStage Medical, Inc.Program year20251 payment
- Bard Peripheral Vascular, Inc.Program year20243 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
61.9%Calcium channel blocker13.1%Amlodipine Besylate100%Part D≥11 patientsACE inhibitor12.5%Lisinopril100%Part D≥15 patients+ 6 more classes in this area
Metabolism & gastrointestinal
23.5%SGLT2 inhibitor14.9%Jardiance63%Farxiga37%Part D<11 patientsVitamin D3 Analog5%Calcitriol100%Part D<11 patients+ 1 more class in this area
Anti-infectives
9.4%Short-acting sulfonamides9.4%Sulfamethoxazole-Trimethoprim100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Outpatient Optimal Start Effect on Health Care Costs During Transition to Dialysis
Journal of the American Society of Nephrology
2025 - Clinical Utility and Cost-Effectiveness of SGLT2 Inhibitors in a Full Risk Value-Based Care Model
Journal of the American Society of Nephrology
2025 - IN.PACT AV Access Trial: Economic Evaluation of Drug-Coated Balloon Treatment for Dysfunctional Arteriovenous Fistulae Based on 12-Month Clinical Outcomes
Journal of Vascular and Interventional Radiology
2022 - Nephrologists' Value Exceeds RVU Calculations2021
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”